Plozasiran is the first FDA-approved drug for familial chylomicronemia syndrome, reducing triglycerides as an adjunct to diet ...

Women under age 50 who consume higher amounts of ultraprocessed foods (UPFs) face significantly increased odds of developing ...

Jasmine Eugene, PharmD, explains how pharmacists practicing at the top of their license improve rural oncology access and ...

Clark Alsfeld, MD, discusses how telemedicine, pharmacists, and evolving policies help overcome financial and geographic ...

Patients seeking access to oral acute myeloid leukemia (AML) medications face complex insurance approval processes that can ...

Panelists discuss how managing oral therapy toxicities requires preemptive planning, multidisciplinary team involvement, ...

Panelists discuss how prescription digital therapeutics like Daylight show promise for treating depression and anxiety but ...

Panelists discuss how digital therapeutics could address the enormous unmet need for treating negative symptoms in the 60% of ...

GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...

Lower middle- and low-income countries are less likely to receive market authorization for drugs that were trialed within their state and approved by the FDA within 5 years of approval when compared ...

A total of 96.9% of the participants had heard of PrEP, of which 90.9% had heard of daily oral PrEP, 76.9% had heard of event-driven PrEP, and only 21.7% had heard of CAB-LA. There were 44.5% of the ...

Danielle Roman, PharmD, BCOP, discusses the challenges of accessing genomic test results and managing prior authorization in patient care for breast cancer.